New combo therapy aims to shrink Hard-to-Treat breast tumors
NCT ID NCT06942234
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tests a new drug called JSKN016 combined with chemotherapy or immunotherapy for people with advanced HER2-negative breast cancer that cannot be surgically removed or has spread. About 180 adults in China will join, and researchers will measure how many patients' tumors shrink or disappear. The goal is to find a safe and effective treatment option for this type of breast cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INOPERABLE LOCALLY ADVANCED HER2-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer center
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.